Moyret-Lalle Caroline, Falette Nicole, Grelier Gaël, Puisieux Alain
Inserm, U590. F-69008, Lyon, France.
Bull Cancer. 2008 Oct;95(10):923-30. doi: 10.1684/bdc.2008.0726.
Oncogenesis and tumour progression are caused by the progressive accumulation of genetic and epigenetic abnormalities in pre-cancerous and cancerous cells, conferring increased capabilities of proliferation and survival. Recent technological advances, including the development of CGH arrays and high-throughput sequencing, have made it possible to map the genetic landscape of human cancers. Molecular characterisation studies have provided key insights into the disease mechanisms that can be used for the design of tailored therapies and have led to the identification of specific biomarkers for guiding patient management. Nevertheless, the genetic instability of cancer cells and the consecutive intra-tumoral heterogeneity remain critical constraints in the context of the emergence of targeted therapies.
肿瘤发生和肿瘤进展是由癌前细胞和癌细胞中遗传和表观遗传异常的逐步积累引起的,赋予了细胞更强的增殖和存活能力。包括比较基因组杂交阵列(CGH阵列)和高通量测序技术在内的最新技术进展,使得绘制人类癌症的基因图谱成为可能。分子特征研究为疾病机制提供了关键见解,可用于设计个性化治疗方案,并已导致识别出用于指导患者管理的特定生物标志物。然而,在靶向治疗出现的背景下,癌细胞的基因不稳定性和随之而来的肿瘤内异质性仍然是关键限制因素。